Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Director Purchases $761,906.00 in Stock
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Director Xiaopeng Li purchased 89,636 shares of the business’s stock in a transaction on Wednesday, August 2nd. The stock was purchased at an average cost of $8.50 per share, with a total value of $761,906.00. Following the acquisition, the director now owns 206,350 shares in the company, valued at $1,753,975. The purchase was disclosed in a legal filing with the SEC, which is available at this link.
Shares of Oramed Pharmaceuticals Inc. (NASDAQ ORMP) traded down 0.74% during trading on Thursday, hitting $8.03. The stock had a trading volume of 18,775 shares. The stock has a market capitalization of $106.97 million, a P/E ratio of 9.23 and a beta of 0.38. The stock’s 50-day moving average is $8.01 and its 200-day moving average is $7.14. Oramed Pharmaceuticals Inc. has a 12-month low of $5.70 and a 12-month high of $9.17.
Separately, HC Wainwright set a $25.00 price target on Oramed Pharmaceuticals and gave the company a “buy” rating in a report on Monday, May 22nd.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Receive News & Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.